Kanāda - angļu - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride); selenium (selenious acid); iodide (sodium iodide) - solution - 5mg; 1mg; 0.5mg; 10mcg; 60mcg; 75mcg - zinc (zinc sulfate) 5mg; copper (cupric sulfate) 1mg; manganese (manganese sulfate) 0.5mg; chromium (chromic chloride) 10mcg; selenium (selenious acid) 60mcg; iodide (sodium iodide) 75mcg - replacement preparations

Kanāda - angļu - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride) - solution - 5mg; 1mg; 0.5mg; 10mcg - zinc (zinc sulfate) 5mg; copper (cupric sulfate) 1mg; manganese (manganese sulfate) 0.5mg; chromium (chromic chloride) 10mcg - replacement preparations

Kanāda - angļu - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride) - solution - 1mg; 0.4mg; 0.1mg; 4mcg - zinc (zinc sulfate) 1mg; copper (cupric sulfate) 0.4mg; manganese (manganese sulfate) 0.1mg; chromium (chromic chloride) 4mcg - replacement preparations

Kanāda - angļu - Health Canada

mylan pharmaceuticals ulc - naproxen - tablet (enteric-coated) - 500mg - naproxen 500mg - other nonsteroidal antiimflammatory agents

Kanāda - angļu - Health Canada

mylan pharmaceuticals ulc - naproxen - tablet (enteric-coated) - 250mg - naproxen 250mg - other nonsteroidal antiimflammatory agents

Kanāda - angļu - Health Canada

mylan pharmaceuticals ulc - naproxen - tablet (enteric-coated) - 375mg - naproxen 375mg - other nonsteroidal antiimflammatory agents

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

department of state health services, pharmacy branch - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 25 mg in 1 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin oral solution is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [ see

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sagent pharmaceuticals - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 5 mg in 1 ml - levofloxacin injection in 5% dextrose is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-suscep

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sagent pharmaceuticals - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 5 mg in 1 ml - levofloxacin injection in 5% dextrose is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-suscep

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - alclometasone dipropionate (unii: s56pql4n1v) (alclometasone - unii:136h45tb7b) - alclometasone dipropionate 0.5 mg in 1 g - alclometasone dipropionate cream is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. alclometasone dipropionate cream may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see precautions: pediatric use ). since the safety and efficacy of alclometasone dipropionate cream have not been established in pediatric patients below 1 year of age, the use in this age-group is not recommended. alclometasone dipropionate cream is contraindicated in those patients with a history of hypersensitivity to any of the components in these preparations.